『徳島大学 教育・研究者情報データベース (EDB)』---[学外] /
ID: Pass:

登録内容 (EID=373130)

EID=373130EID:373130, Map:0, LastModified:2021年4月28日(水) 11:24:43, Operator:[高山 哲治], Avail:TRUE, Censor:承認済, Owner:[高山 哲治], Read:継承, Write:継承, Delete:継承.
○種別 (必須): □学術論文 (審査論文) [継承]
○言語 (必須): □英語 [継承]
○招待 (推奨):
○審査 (推奨):
○カテゴリ (推奨):
○共著種別 (推奨):
○学究種別 (推奨):
○組織 (推奨):
○著者 (必須): 1.友成 哲
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
2.佐藤 康史 ([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).地域消化器・総合内科学])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
3. (英) Tani Joji (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
4. (英) Hirose Akira (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
5. (英) Ogawa Chikara (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
6. (英) Morishita Akihiro (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
7.田中 宏典 ([徳島大学.病院.先端医科医療開発研究プロジェクト]/[徳島大学.病院.診療科.内科.消化器内科])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨): □**** [ユーザ]
[継承]
8.田中 貴大
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨): □**** [ユーザ]
[継承]
9.谷口 達哉
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨): □**** [ユーザ]
[継承]
10.岡本 耕一 ([徳島大学.病院.診療科.内科.消化器内科])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
11.曽我部 正弘 ([徳島大学.キャンパスライフ健康支援センター])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
12.宮本 弘志 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学]/[徳島大学.病院.診療科.内科.消化器内科])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
13.六車 直樹
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
14. (英) Uchida Kazushige (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
15. (英) Masaki Tsutomu (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
16.高山 哲治 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
○題名 (必須): □(英) Comparison of therapeutic outcomes of Sorafenib and Lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.  (日)    [継承]
○副題 (任意):
○要約 (任意): □(英) The optimal choice between sorafenib (SOR) or lenvatinib (LEN) as the first-line treatment for unresectable hepatocellular carcinoma (u-HCC) remains debatable. Using propensity score matching, this study compares the outcomes of SOR and LEN in the molecular-targeted agent (MTA) sequential treatment of u-HCC patients. This retrospective, multicenter, observational study recruited 137 u-HCC patients who underwent primary treatment with LEN (n = 52) or SOR (n = 85) between June 2017 and June 2020 after regorafenib was approved as the secondary treatment for u-HCC. Propensity score matching was used to reduce confounding, resulting in the selection of 104 patients (n = 52 for the SOR and LEN cohorts). The median overall survival was 21.8 months for LEN and 20.4 months for SOR. LEN exhibited significantly greater therapeutic efficacy as compared to SOR (objective response rate: 3.8% [SOR] vs. 42.3% [LEN], P <0.01; progression-free survival: 10 months [LEN] vs. 5.1 months [SOR], P <0.01). No significant intergroup differences were noted in the rate of transition to secondary MTA treatments (SOR: 58.7%; LEN: 48.4%), adverse events (SOR: 86%; LEN: 95%), and maintenance of the Child-Pugh (CP) score during treatment. Compared to non-MTA treatments, secondary MTA treatment achieved a greater improvement in survival ( 4.3 months vs. 2.8 months, P=0.0047). Multivariate analysis demonstrated that the CP score (P <0.01) and alpha-fetoprotein level (P <0.01) were independent prognostic factors. Both SOR and LEN treatments showed a clinically comparable therapeutic efficacy as the first-line treatments for u-HCC patients in an MTA sequential therapy.  (日)    [継承]
○キーワード (推奨):
○発行所 (推奨):
○誌名 (必須): □Hepatology Research (日本肝臓学会)
(pISSN: 1386-6346, eISSN: 1872-034X)

○ISSN (任意): □1386-6346
ISSN: 1386-6346 (pISSN: 1386-6346, eISSN: 1872-034X)
Title: Hepatology research : the official journal of the Japan Society of Hepatology
Title(ISO): Hepatol Res
Supplier: Japan Society of Hepatology
Publisher: Wiley Publishing
 (NLM Catalog)   (医中誌Web)   (Wiley)   (Scopus)   (CrossRef)  (Scopus information is found. [need login])
[継承]
[継承]
○巻 (必須): □51 [継承]
○号 (必須): □4 [継承]
○頁 (必須): □472 481 [継承]
○都市 (任意):
○年月日 (必須): □西暦 2021年 4月 初日 (令和 3年 4月 初日) [継承]
○URL (任意):
○DOI (任意): □10.1111/hepr.13597    (→Scopusで検索) [継承]
○PMID (任意): □33238074    (→Scopusで検索) [継承]
○CRID (任意):
○WOS (任意):
○Scopus (任意):
○評価値 (任意):
○被引用数 (任意):
○指導教員 (推奨):
○備考 (任意): 1.(英) Article.ELocationID: 10.1111/hepr.13597  (日)    [継承]
2.(英) Article.PublicationTypeList.PublicationType: Journal Article  (日)    [継承]

標準的な表示

和文冊子 ● Tetsu Tomonari, Yasushi Sato, Joji Tani, Akira Hirose, Chikara Ogawa, Akihiro Morishita, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Kazushige Uchida, Tsutomu Masaki and Tetsuji Takayama : Comparison of therapeutic outcomes of Sorafenib and Lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis., Hepatology Research, Vol.51, No.4, 472-481, 2021.
欧文冊子 ● Tetsu Tomonari, Yasushi Sato, Joji Tani, Akira Hirose, Chikara Ogawa, Akihiro Morishita, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Kazushige Uchida, Tsutomu Masaki and Tetsuji Takayama : Comparison of therapeutic outcomes of Sorafenib and Lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis., Hepatology Research, Vol.51, No.4, 472-481, 2021.

関連情報

Number of session users = 2, LA = 1.02, Max(EID) = 417270, Max(EOID) = 1130234.